PL3708178T3 - Peptyd do stosowania w zapobieganiu lub leczeniu zwyrodnienia plamki żółtej - Google Patents

Peptyd do stosowania w zapobieganiu lub leczeniu zwyrodnienia plamki żółtej

Info

Publication number
PL3708178T3
PL3708178T3 PL20156769.0T PL20156769T PL3708178T3 PL 3708178 T3 PL3708178 T3 PL 3708178T3 PL 20156769 T PL20156769 T PL 20156769T PL 3708178 T3 PL3708178 T3 PL 3708178T3
Authority
PL
Poland
Prior art keywords
peptide
preventing
macular degeneration
treating macular
treating
Prior art date
Application number
PL20156769.0T
Other languages
English (en)
Polish (pl)
Inventor
Shibo Tang
Liping Liu
Xiaoling Liang
Original Assignee
Stealth Biotherapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Inc. filed Critical Stealth Biotherapeutics Inc.
Publication of PL3708178T3 publication Critical patent/PL3708178T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20156769.0T 2009-08-24 2010-08-23 Peptyd do stosowania w zapobieganiu lub leczeniu zwyrodnienia plamki żółtej PL3708178T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23644009P 2009-08-24 2009-08-24
US23774509P 2009-08-28 2009-08-28
US34847010P 2010-05-26 2010-05-26

Publications (1)

Publication Number Publication Date
PL3708178T3 true PL3708178T3 (pl) 2024-05-13

Family

ID=43628336

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10812524T PL2470191T3 (pl) 2009-08-24 2010-08-23 Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych
PL20156769.0T PL3708178T3 (pl) 2009-08-24 2010-08-23 Peptyd do stosowania w zapobieganiu lub leczeniu zwyrodnienia plamki żółtej

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10812524T PL2470191T3 (pl) 2009-08-24 2010-08-23 Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych

Country Status (17)

Country Link
US (8) US8470784B2 (enExample)
EP (18) EP3338788A1 (enExample)
JP (8) JP6120399B2 (enExample)
CN (3) CN102625709A (enExample)
CA (1) CA2772094C (enExample)
DK (2) DK2470191T3 (enExample)
ES (3) ES2964555T3 (enExample)
FI (1) FI3708178T3 (enExample)
HK (4) HK1204958A1 (enExample)
HR (1) HRP20231277T1 (enExample)
HU (1) HUE064800T2 (enExample)
LT (1) LT3708178T (enExample)
PL (2) PL2470191T3 (enExample)
PT (2) PT3708178T (enExample)
SI (2) SI3708178T1 (enExample)
SM (1) SMT202300433T1 (enExample)
WO (1) WO2011025734A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2901966B2 (en) 2008-09-29 2024-06-26 Edwards Lifesciences CardiAQ LLC Heart valve
CA2739275C (en) 2008-10-01 2017-01-17 Impala, Inc. Delivery system for vascular implant
JP2012523894A (ja) 2009-04-15 2012-10-11 カルディアック バルブ テクノロジーズ，インコーポレーテッド 血管インプラント及びその配設システム
CN102625709A (zh) 2009-08-24 2012-08-01 康肽德生物医药技术有限公司 用于预防或治疗眼科病症的方法和组合物
WO2011116007A1 (en) 2010-03-15 2011-09-22 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US20110269807A1 (en) * 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
US8579964B2 (en) 2010-05-05 2013-11-12 Neovasc Inc. Transcatheter mitral valve prosthesis
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
JP2013539137A (ja) 2010-10-01 2013-10-17 ゼット１２４ ユーザインタフェースにおけるドラッグ移動ジェスチャ
CN103796665B (zh) * 2011-03-24 2018-10-30 康奈尔大学 芳香族阳离子肽及其用途
US9308087B2 (en) 2011-04-28 2016-04-12 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
US9554897B2 (en) 2011-04-28 2017-01-31 Neovasc Tiara Inc. Methods and apparatus for engaging a valve prosthesis with tissue
CN102327600A (zh) * 2011-09-14 2012-01-25 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防和治疗辐射损伤的rx31肽
US8842057B2 (en) 2011-09-27 2014-09-23 Z124 Detail on triggers: transitional states
EP3466439A1 (en) * 2011-12-09 2019-04-10 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN104244964A (zh) * 2012-02-22 2014-12-24 康肽德生物医药技术有限公司 用于预防或治疗眼科病状的方法和组合物
US9636378B2 (en) * 2012-03-30 2017-05-02 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment neuropathy
US9345573B2 (en) 2012-05-30 2016-05-24 Neovasc Tiara Inc. Methods and apparatus for loading a prosthesis onto a delivery system
CN110090304A (zh) * 2012-08-02 2019-08-06 康德生物医疗技术公司 用于治疗动脉粥样硬化的方法
EP2913062B1 (en) * 2012-10-24 2019-05-08 Japan Innovative Therapeutics, Inc. Therapeutic or prophylactic agent for retinopathy of prematurity and method of testing for retinopathy of prematurity
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
JP6839490B2 (ja) * 2013-03-01 2021-03-10 ステルス バイオセラピューティックス コープ ミトコンドリア疾患の治療のための方法
CN115990241A (zh) 2013-03-01 2023-04-21 康德生物医疗有限公司 预防或治疗巴斯综合征的方法和组合物
US10583002B2 (en) 2013-03-11 2020-03-10 Neovasc Tiara Inc. Prosthetic valve with anti-pivoting mechanism
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US9681951B2 (en) 2013-03-14 2017-06-20 Edwards Lifesciences Cardiaq Llc Prosthesis with outer skirt and anchors
US9572665B2 (en) 2013-04-04 2017-02-21 Neovasc Tiara Inc. Methods and apparatus for delivering a prosthetic valve to a beating heart
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US20160193278A1 (en) * 2013-08-01 2016-07-07 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
CA2920735A1 (en) * 2013-08-12 2015-02-19 Stealth Biotherapeutics Corp Combination therapy for the treatment of ischemia-reperfusion injury
WO2015061658A1 (en) * 2013-10-25 2015-04-30 Children's Medical Center Corporation Methods of treating or preventing vascular diseases of the retina
CN105939759B (zh) * 2013-12-02 2020-01-17 康德生物医疗技术公司 用于治疗白癜风的组合物和方法
WO2015103577A1 (en) * 2014-01-06 2015-07-09 Stealth Peptides International, Inc. Methods and compositions for preventing or treating dominant optic atrophy
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
JP6692795B2 (ja) 2014-04-10 2020-05-13 ランケナー インスティテュート フォー メディカル リサーチ 眼疾患および眼障害の治療のための方法および組成物
US20170182117A1 (en) * 2014-05-28 2017-06-29 Stealth Biotherapeutics Corp Therapeutic compositions including therapeutic small molecules and uses thereof
EP3233174B1 (en) * 2014-12-19 2021-03-31 Kemin Industries, Inc. Intraocular delivery of bioactive molecules using iontophoresis
WO2017117512A2 (en) 2015-12-30 2017-07-06 Marshall University Research Corporation Compositions and methods for treating retinopathy
WO2017156403A1 (en) * 2016-03-11 2017-09-14 Stealth Biotherapeutics Crystalline salt forms
AU2017250002B2 (en) 2016-04-11 2022-12-22 University Of Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
CN109563131A (zh) 2016-04-11 2019-04-02 卡诺有限责任公司 手性肽
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
JP7006990B2 (ja) * 2017-11-17 2022-02-10 セリックス バイオ プライヴェート リミテッド 眼障害の処置のための組成物及び方法
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
PL424452A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
WO2019213358A1 (en) * 2018-05-03 2019-11-07 Alimera Sciences, Inc. Methods of treating retinal diseases
WO2020018455A1 (en) * 2018-07-16 2020-01-23 Stealth Biotherapeutics Corp Compositions and methods for the treatment of traumatic optic neuropathy
CA3113528A1 (en) * 2018-09-21 2020-03-26 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
JP2022516796A (ja) * 2019-01-12 2022-03-02 セリックス バイオ プライヴェート リミテッド 選択的αアドレナリン受容体作用薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用
WO2020214990A1 (en) * 2019-04-17 2020-10-22 Ascidian Therapeutics, Inc. Abca4 cell line and methods of use
JP2020174859A (ja) * 2019-04-17 2020-10-29 学校法人日本医科大学 網膜剥離が生じるリスクが低い網膜変性症（ｒｄ）モデルマウスを取得する方法
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
EP3976079A1 (en) * 2019-05-28 2022-04-06 Elgan Pharma Ltd. Compositions and methods for treating retinopathy
JP2023518853A (ja) * 2020-03-25 2023-05-08 アウフバウ・メディカル・イノベイションズ・リミテッド 緑内障のためのプロセスおよび薬剤
KR20230124625A (ko) * 2020-12-24 2023-08-25 산텐 세이야꾸 가부시키가이샤 에피나스틴 또는 그의 염과 황계 항산화제를 함유하는경피 투여용 의약 조성물
AU2022370358A1 (en) * 2021-10-20 2024-05-02 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023069255A1 (en) * 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023086873A1 (en) * 2021-11-10 2023-05-19 Reverspah Llc Methods and compositions for treating cancer
CN114099678A (zh) * 2021-11-23 2022-03-01 浙江大学 基于Keap1-Nrf2信号通路的晶状体损伤抑制剂
KR102662922B1 (ko) * 2022-05-31 2024-05-03 주식회사 세네릭스 신규의 d-아미노산 유도체 및 이를 포함하는 약학 조성물

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
ES2085865T3 (es) 1988-06-30 1996-06-16 Astra Ab Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean.
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
DE69630918T2 (de) 1995-06-09 2004-10-28 Hisamitsu Pharmaceutical Co., Inc., Tosu Matrix für Iontophorese
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
AU1818299A (en) 1997-12-10 1999-06-28 Washington University Anti-pathogen system and methods of use thereof
AU3965699A (en) 1998-04-24 1999-11-16 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
CA2386239A1 (en) 1999-10-04 2001-04-12 University Of Medicine And Dentistry Of New Jersey Methods for identifying rna binding compounds
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
JP2001270832A (ja) * 2000-03-27 2001-10-02 Ito En Ltd 網膜障害予防剤
DE60143945D1 (de) 2000-07-18 2011-03-10 Cornell Res Foundation Inc Medizinische verwendung von agonisten des mu-opioid rezeptors
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
EP1542664A4 (en) * 2002-08-14 2008-04-16 Med College Georgia Res Inst METHOD AND COMPOSITIONS FOR TREATING MACULA AND RETINA DISEASES
US7354574B2 (en) * 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20060172972A1 (en) 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US7576061B2 (en) 2003-02-04 2009-08-18 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
JP2004323486A (ja) * 2003-04-30 2004-11-18 National Institute Of Advanced Industrial & Technology 網膜及び／又はブドウ膜疾患の予防乃至治療用点眼薬
DK2604285T3 (en) 2003-05-01 2014-12-01 Cornell Res Foundation Inc Method and carrier complex for delivering molecules to cells
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
NZ549393A (en) * 2004-01-23 2009-07-31 Cornell Res Foundation Inc Methods for reducing oxidative damage
SI1755616T1 (sl) 2004-04-08 2014-04-30 Eye Co Pty Ltd. Zdravljenje eksudativne retinopatije z mineralkortikoidi
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
JP4760111B2 (ja) 2005-04-26 2011-08-31 株式会社セガ 映像オブジェクト表現用データ構造生成プログラム、映像オブジェクト表現用データ構造生成方法、映像ソフト開発装置、映像処理プログラム、映像処理方法、映像処理装置、映像オブジェクト表現用データ構造、および、記録媒体
US8088773B2 (en) 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
JP2007043629A (ja) * 2005-06-30 2007-02-15 Sony Corp グラフィック・ユーザ・インタフェース装置と操作入力処理方法及び双方向コミュニケーション装置
WO2007011874A2 (en) 2005-07-15 2007-01-25 Chakshu Research Inc. Formulation and method for administration of ophthalmologically active agents
US7541340B2 (en) * 2005-09-16 2009-06-02 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
AU2006300222A1 (en) * 2005-10-05 2007-04-19 Aqumen Biopharmaceuticals K.K. Method of inhibiting angiogenesis by using ephrin B2
US20070259377A1 (en) 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
TW200744627A (en) 2006-02-21 2007-12-16 Pfizer Prod Inc Methods for the treatment of macular degeneration and related eye conditions
AU2007238677B2 (en) * 2006-04-14 2011-03-10 Novartis Ag Use of IL-I antibodies for treating ophthalmic disorders
US20080027082A1 (en) 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
DE102006042329B4 (de) * 2006-09-01 2008-08-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zum selektiven plasmachemischen Trockenätzen von auf Oberflächen von Silicium-Wafern ausgebildetem Phosphorsilikatglas
BRPI0720038A2 (pt) 2006-12-11 2013-12-24 Univ Utah Res Found Métodos para inibir a permeabilidade vascular em tecido, para triar ou avaliar um agente que inibe a permeabilidade vascular, para tratar ou prevenir a síndrome da angústia respiratória, a retinopatia de prematuridade, a retinopatia diabética e a degeneração macular úmida em um indivíduo, para tratar indivíduos com sugestões repulsivas ou miméticos e para promover a angiogênese em um tecido, polipeptídeo isolado, ácido nucleico isolado, e, vetor
JP2008195655A (ja) * 2007-02-14 2008-08-28 Kitasato Institute 糖尿病白内障の治療剤
WO2008111497A1 (ja) * 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
KR20100016140A (ko) 2007-05-25 2010-02-12 산텐 세이야꾸 가부시키가이샤 가령 황반 변성의 예방 또는 치료제
JP5453320B2 (ja) 2008-02-07 2014-03-26 コーネル ユニヴァーシティー インスリン抵抗性を防止または処置するための方法
EP3741381B1 (en) * 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury
EP2408463B1 (en) 2009-03-20 2016-10-19 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention and treatment of burn injuries and secondary complications
FR2945540B1 (fr) 2009-05-15 2012-06-08 Rhodia Operations Procede de preparation de mousse polyamide et mousse susceptible d'etre obtenue par ce procede
CN105031605A (zh) 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
CN102625709A (zh) * 2009-08-24 2012-08-01 康肽德生物医药技术有限公司 用于预防或治疗眼科病症的方法和组合物
EP2733150A1 (en) * 2010-01-25 2014-05-21 Cornell University Aromatic-cationic peptides and uses of same
WO2011106717A1 (en) * 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3290433A1 (en) 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
HK1197028A1 (en) 2011-06-14 2015-01-02 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
WO2014210056A1 (en) * 2013-06-27 2014-12-31 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
US20160199437A1 (en) * 2015-01-08 2016-07-14 D. Travis Wilson Therapeutic compositions including iron chelators and uses thereof
US20160228491A1 (en) * 2015-02-09 2016-08-11 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof

Also Published As

Publication number Publication date
US11944662B2 (en) 2024-04-02
JP2022001609A (ja) 2022-01-06
EP3292868A1 (en) 2018-03-14
US11612633B2 (en) 2023-03-28
US20230346874A1 (en) 2023-11-02
EP4596049A3 (en) 2025-08-13
EP3524256A1 (en) 2019-08-14
EP2962695A1 (en) 2016-01-06
HK1172833A1 (en) 2013-05-03
FI3708178T3 (fi) 2023-11-09
US9023807B2 (en) 2015-05-05
JP2023179733A (ja) 2023-12-19
ES2964555T3 (es) 2024-04-08
ES2487633T3 (es) 2014-08-22
JP2013502460A (ja) 2013-01-24
EP3708178B1 (en) 2023-10-04
HK1204958A1 (en) 2015-12-11
HK1217900A1 (en) 2017-01-27
US20200061147A1 (en) 2020-02-27
JP6120399B2 (ja) 2017-04-26
PT3708178T (pt) 2023-11-16
EP2470191B1 (en) 2014-05-07
EP2470191A1 (en) 2012-07-04
LT3708178T (lt) 2023-12-27
SMT202300433T1 (it) 2024-01-10
EP3485896A1 (en) 2019-05-22
EP2470191A4 (en) 2013-04-17
US20230381264A1 (en) 2023-11-30
CN107412722A (zh) 2017-12-01
JP2020128431A (ja) 2020-08-27
CA2772094A1 (en) 2011-03-03
EP2990049A1 (en) 2016-03-02
CA2772094C (en) 2018-04-03
EP3338788A1 (en) 2018-06-27
WO2011025734A1 (en) 2011-03-03
EP3708178A1 (en) 2020-09-16
US20170326197A1 (en) 2017-11-16
US20110177047A1 (en) 2011-07-21
US9549963B2 (en) 2017-01-24
EP4596049A2 (en) 2025-08-06
EP4302829B1 (en) 2025-05-21
JP6381737B2 (ja) 2018-08-29
HK1247821A1 (zh) 2018-10-05
EP3124036A1 (en) 2017-02-01
JP7642965B2 (ja) 2025-03-11
EP2826487A1 (en) 2015-01-21
SI2470191T1 (sl) 2014-08-29
EP2957291A1 (en) 2015-12-23
US20210154259A1 (en) 2021-05-27
PL2470191T3 (pl) 2014-09-30
US10188692B2 (en) 2019-01-29
US8470784B2 (en) 2013-06-25
EP3150215A1 (en) 2017-04-05
HUE064800T2 (hu) 2024-04-28
EP2813235A1 (en) 2014-12-17
CN102625709A (zh) 2012-08-01
US20140044689A1 (en) 2014-02-13
EP3318264A1 (en) 2018-05-09
US20160058825A1 (en) 2016-03-03
HK1206258A1 (en) 2016-01-08
SI3708178T1 (sl) 2024-01-31
DK3708178T3 (da) 2023-11-13
JP2018162329A (ja) 2018-10-18
HRP20231277T1 (hr) 2024-02-02
EP3494983A1 (en) 2019-06-12
JP2016026188A (ja) 2016-02-12
CN105056206A (zh) 2015-11-18
EP3175862A1 (en) 2017-06-07
ES3036317T3 (en) 2025-09-17
PT2470191E (pt) 2014-06-12
JP2017141306A (ja) 2017-08-17
JP6332757B2 (ja) 2018-05-30
DK2470191T3 (da) 2014-07-07
EP4302829A2 (en) 2024-01-10
EP4302829A3 (en) 2024-03-27
JP2025181975A (ja) 2025-12-11

Similar Documents

Publication Publication Date Title
PL3708178T3 (pl) Peptyd do stosowania w zapobieganiu lub leczeniu zwyrodnienia plamki żółtej
IL274206A (en) MASP-2 suppressors for use in the treatment of radiation heredity syndrome
EP2741711A4 (en) IMPROVEMENTS FOR PROSTHETIC VALVES AND ASSOCIATED INVENTIONS
PT2187880E (pt) Composições e métodos para o tratamento da degenerescência macular
BRPI1006802A2 (pt) artigos absorvente para vestir em duas peças
SI2560653T1 (sl) Določeni aminopirimidini, sestavki le-teh in postopki za njihovo uporabo
BR112012001906A2 (pt) artigo abrasivo e método de formação
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
PL2252317T3 (pl) Leczenie zwyrodnienia plamki żółtej
DK2352876T3 (da) Behandlet tekstilmateriale til anvendelse i vandige miljøer
EP2796615A4 (en) DRYER AND METHOD OF CLEANING EVAPORATOR IN A DRYER
EP2648523A4 (en) MELT-PROCESSED ANTIMICROBIAL COMPOSITION
IL229381B (en) Brilacitidine and its results for use in the treatment of mucositis
IL236823A0 (en) Preparations for use in the treatment of bone defects
EP2451983A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING MACULATE GENERATION
PT2337573E (pt) Soro de leite no tratamento de linfocitopenia
EP2708223A4 (en) COLORING AGENT AND USE THEREOF
PL2621517T5 (pl) Kompozycja do stosowania w leczeniu niepłodności
IL228319A (en) Azul carpentry, pharmaceuticals containing them and their use for prevention or treatment of baldness
ZA201108151B (en) Method and composition for treating macular degeneration
PL2692345T3 (pl) Kompozycja farmaceutyczna do zapobiegania lub leczenia zwyrodnienia plamki żółtej
PL2606032T3 (pl) Kompozycja i sposoby terapii glejakaep
PT2658536T (pt) Gemcabeno e derivados para tratamento da pancreatite
PL2392329T3 (pl) Kompozycje do stosowania w leczeniu zespołów mielodysplastycznych
PL2548585T3 (pl) Kompozycja czyszcząca i/lub dezynfekująca